Safety and efficacy of colchicine in Covid-19 treatment: Systematic review and meta-analysis

IF 1.7 Q2 Medicine

Advances in integrative medicine Pub Date : 2025-09-10 DOI:10.1016/j.aimed.2025.100571

Ahmed Hosney Nada , Ismail A. Ibrahim , Nada Khalid Asar , Abdulrahman Qenawy , Mariam M. Mohammed , Mohamed Wagdy , Heidi Sherif Farouk

{"title":"Safety and efficacy of colchicine in Covid-19 treatment: Systematic review and meta-analysis","authors":"Ahmed Hosney Nada , Ismail A. Ibrahim , Nada Khalid Asar , Abdulrahman Qenawy , Mariam M. Mohammed , Mohamed Wagdy , Heidi Sherif Farouk","doi":"10.1016/j.aimed.2025.100571","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Colchicine is an anti-inflammatory drug used for the treatment of gout and other autoinflammatory conditions. Several trials reported promising results of the efficacy of colchicine in Covid-19 due to its anti-inflammatory properties. However, applying these results to clinical settings remains the subject of ongoing research.</div></div><div><h3>Methods</h3><div>We performed a systematic review and meta-analysis on the efficacy and safety of colchicine in the treatment of Covid-19. PubMed, Cochrane Library, Web of Science, and Scopus were searched for relevant studies. The primary outcomes were 28-day mortality, invasive mechanical ventilation, non-invasive mechanical ventilation, and ICU admissions. The risk ratio was used to compare effectiveness between the two groups. Subgroup analysis was done for C-reactive protein and duration of hospitalization.</div></div><div><h3>Results</h3><div>17 randomized controlled trials with a total of 25478 patients were included. The overall Risk ratio didn’t favor any of the two groups in terms of 28-day mortality (RR = 1.03, 95 % CI [0.93:1.15], P = 0.58), non-invasive mechanical ventilation (RR = 0.81, 95 % CI [0.44:1.48], P = 0.49), ICU admission (RR = 0.89, 95 % CI [0.56:1.41], P = 0.62).</div><div>The overall mean difference (MD) did not show statistical significance between both groups in terms of C- reactive protein (CRP) (mg/dl) (MD = −1.21, 95 % CI [-2.42:0.01], P = 0.05), lactate dehydrogenase (LDH) (U/L) (MD = 50.95, 95 % CI [-92.07: 193.98], Ferritin (ng/ml) (MD = 128.08, 95 % CI [51.97:204.18], P = 0.001), ICU length of stay (MD = −0.09, 95 % CI [-0.34:0.15], P = 0.45) and duration of hospitalization (MD = −0.41, 95 % CI [-1.56:0.73], P = 0.48).</div></div><div><h3>Conclusion</h3><div>In Covid-19 treatment, colchicine didn’t result in significant benefits in terms of clinical outcomes. More large-scale randomized clinical trials with standardized dosages and long-term follow-up are needed for further investigation into the colchicine effect.</div></div>","PeriodicalId":7343,"journal":{"name":"Advances in integrative medicine","volume":"12 4","pages":"Article 100571"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in integrative medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212958825001302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Colchicine is an anti-inflammatory drug used for the treatment of gout and other autoinflammatory conditions. Several trials reported promising results of the efficacy of colchicine in Covid-19 due to its anti-inflammatory properties. However, applying these results to clinical settings remains the subject of ongoing research.

Methods

We performed a systematic review and meta-analysis on the efficacy and safety of colchicine in the treatment of Covid-19. PubMed, Cochrane Library, Web of Science, and Scopus were searched for relevant studies. The primary outcomes were 28-day mortality, invasive mechanical ventilation, non-invasive mechanical ventilation, and ICU admissions. The risk ratio was used to compare effectiveness between the two groups. Subgroup analysis was done for C-reactive protein and duration of hospitalization.

Results

17 randomized controlled trials with a total of 25478 patients were included. The overall Risk ratio didn’t favor any of the two groups in terms of 28-day mortality (RR = 1.03, 95 % CI [0.93:1.15], P = 0.58), non-invasive mechanical ventilation (RR = 0.81, 95 % CI [0.44:1.48], P = 0.49), ICU admission (RR = 0.89, 95 % CI [0.56:1.41], P = 0.62).

The overall mean difference (MD) did not show statistical significance between both groups in terms of C- reactive protein (CRP) (mg/dl) (MD = −1.21, 95 % CI [-2.42:0.01], P = 0.05), lactate dehydrogenase (LDH) (U/L) (MD = 50.95, 95 % CI [-92.07: 193.98], Ferritin (ng/ml) (MD = 128.08, 95 % CI [51.97:204.18], P = 0.001), ICU length of stay (MD = −0.09, 95 % CI [-0.34:0.15], P = 0.45) and duration of hospitalization (MD = −0.41, 95 % CI [-1.56:0.73], P = 0.48).

Conclusion

In Covid-19 treatment, colchicine didn’t result in significant benefits in terms of clinical outcomes. More large-scale randomized clinical trials with standardized dosages and long-term follow-up are needed for further investigation into the colchicine effect.

查看原文本刊更多论文

秋水仙碱治疗Covid-19的安全性和有效性：系统评价和荟萃分析

背景：秋水仙碱是一种抗炎药物，用于治疗痛风和其他自身炎症。由于秋水仙碱的抗炎特性，一些试验报告了秋水仙碱对Covid-19的疗效有希望的结果。然而，将这些结果应用于临床环境仍然是正在进行的研究的主题。方法对秋水仙碱治疗新冠肺炎的疗效和安全性进行系统评价和meta分析。检索PubMed、Cochrane Library、Web of Science和Scopus等相关研究。主要结局为28天死亡率、有创机械通气、无创机械通气和ICU入院情况。风险比用于比较两组间的疗效。对c反应蛋白和住院时间进行亚组分析。结果纳入17项随机对照试验，共纳入25478例患者。整体的风险比不支持任何两组28天的死亡率(RR = 1.03, 95 % CI [0.93:1.15], P = 0.58),非侵入性机械通气(RR = 0.81, 95 % CI [0.44:1.48], P = 0.49),入住ICU (RR = 0.89, 95 % CI [0.56:1.41], P = 0.62)。总体平均差(MD)两组之间没有统计学意义的C -反应蛋白(CRP) (mg / dl) (MD =−1.21,95 % CI [-2.42:0.01], P = 0.05),乳酸脱氢酶(LDH) (U / L) (MD = 50.95, 95 % CI(-92.07: 193.98),铁蛋白(ng / ml) (MD = 128.08, 95 % CI [51.97:204.18], P = 0.001),ICU滞留时间(MD =−0.09,95 % CI [-0.34:0.15], P = 0.45),住院时间(MD =−0.41,95 % CI [-1.56:0.73], P = 0.48)。结论秋水仙碱在新冠肺炎治疗中的临床效果不明显。为了进一步研究秋水仙碱的作用，需要更多标准化剂量的大规模随机临床试验和长期随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in integrative medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

3.20

自引率

11.80%

发文量

审稿时长

15 weeks

期刊介绍： Advances in Integrative Medicine (AIMED) is an international peer-reviewed, evidence-based research and review journal that is multi-disciplinary within the fields of Integrative and Complementary Medicine. The journal focuses on rigorous quantitative and qualitative research including systematic reviews, clinical trials and surveys, whilst also welcoming medical hypotheses and clinically-relevant articles and case studies disclosing practical learning tools for the consulting practitioner. By promoting research and practice excellence in the field, and cross collaboration between relevant practitioner groups and associations, the journal aims to advance the practice of IM, identify areas for future research, and improve patient health outcomes. International networking is encouraged through clinical innovation, the establishment of best practice and by providing opportunities for cooperation between organisations and communities.